
Imunon Inc (IMNN) Stock Forecast & Price Target
Imunon Inc (IMNN) Analyst Ratings
Bulls say
Imunon Inc demonstrated substantial progress in its clinical pipeline during the first quarter of 2025, marked by the initiation of the OVATION 3 trial, which reflects the company's commitment to advancing innovative treatments. The company is leveraging positive translational and survival data from its Phase 2 OVATION 2 study to launch a targeted registrational effort aimed at addressing significant unmet medical needs in frontline ovarian cancer therapy. This strategic focus not only highlights Imunon's potential for impactful advancements in cancer treatment but also positions the company favorably within the biopharmaceutical industry.
Bears say
Imunon Inc's financial position is a significant concern, highlighted by a cash balance of only $2.9 million as of March 31, 2025. The company is anticipated to require a series of dilutive financings that may occur sooner and under less favorable terms than previously expected. This precarious financial state raises doubts about the company's ability to sustain its operations and advance its clinical programs without substantial funding challenges.
This aggregate rating is based on analysts' research of Imunon Inc and is not a guaranteed prediction by Public.com or investment advice.
Imunon Inc (IMNN) Analyst Forecast & Price Prediction
Start investing in Imunon Inc (IMNN)
Order type
Buy in
Order amount
Est. shares
0 shares